New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin‐like growth factor/AKT/mammalian target of rapamycin pathways

Metformin is a biguanide widely prescribed as an antidiabetic drug for type 2 diabetes mellitus patients. The purpose of the present study was to observe the effects of the new metformin derivative, HL156A, on human oral cancer cell and to investigate its possible mechanisms. It was observed that HL...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Thuy Giang, Jeong, Yun Soo, Kim, Soo‐A, Ahn, Sang‐Gun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834796/
https://www.ncbi.nlm.nih.gov/pubmed/29285837
http://dx.doi.org/10.1111/cas.13482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834796/
https://www.ncbi.nlm.nih.gov/pubmed/29285837
http://dx.doi.org/10.1111/cas.13482

Ejemplares similares